AI-designed lung drug shows signs of reversing biological aging markers in small trial
Six independent aging clocks read treated patients' blood proteins as younger than placebo, but experts note the 42-patient sample is small.
Insilico Medicine reports that rentosertib, a drug candidate designed with generative AI, appears to reverse markers of biological aging, according to a new analysis published in Nature Biotechnology and covered by The Decoder. Rentosertib was originally developed for idiopathic pulmonary fibrosis, a disease that scars lung tissue. A trial last year with 42 patients showed improved lung function, and researchers collected blood samples for protein analysis during the study. The new work applies six independent AI aging clocks to those samples. Aging clocks are models that estimate a body's biological age from blood proteins. All six clocks read the treated patients' protein patterns as biologically younger than those of the placebo group, by up to six years. The finding is early and narrow. Experts quoted by The Decoder call the results encouraging but caution that the small sample size and the absence of testing in healthy people limit what the study can prove. The analysis is retrospective, drawing on blood collected for a trial designed around lung function rather than aging, and the clocks measure protein signatures rather than clinical outcomes. The result matters mainly as a signal for AI-driven drug discovery. It suggests that a compound designed for one indication may carry measurable effects on aging-related biomarkers, which could prompt dedicated follow-up studies. Any claim of slowing or reversing aging in people would require larger, purpose-built trials.